•Law firm Faruqi & Faruqi reminded investors of the September 14, 2026, deadline to seek lead plaintiff status in a class action lawsuit against Regeneron.
•The lawsuit alleges Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo study, resulting in a stock price decline.